First patient enrolled in trial of investigational cannabidiol drug for PTSD

Key takeaways:

• The first patient was enrolled in a trial of an investigational drug containing cannabidiol for the treatment of PTSD.
• The trial is a phase 2 FDA-approved study with plans to enroll 180 patients.

The University of Nebraska Medical Center and Ananda Scientific have enrolled the first patient in a phase 2 clinical trial of an investigational cannabidiol drug for PTSD, according to a press release.

The Nantheia ATL5 (Ananda Scientific), an oral investigational drug, uses Ananda’s proprietary Liquid Structure delivery technology to deliver cannabidiol 100 mg, according to the release.

Matthew Rizzo, MD, FAAN, FANA, the Reynolds Professor and chair of the department of neurological sciences at the University of Nebraska Medical Center, is leading the FDA-approved randomized controlled trial.

“We are very excited to have this important trial underway,” Rizzo said in the release. “Our collaboration with Ananda Scientific is allowing us to advance evidence-based research into new therapeutics for the large PTSD patient population.”

The researchers intend to enroll 180 patients to test Nantheia ATL5’s safety and efficacy profiles, according to the release.